--News Direct--
Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide).
Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Contact Details
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/valeo-pharma-announces-its-onstryv-product-receives-public-reimbursement-in-quebec-162404120